0000012208-24-000025.txt : 20240410 0000012208-24-000025.hdr.sgml : 20240410 20240410161657 ACCESSION NUMBER: 0000012208-24-000025 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240410 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240410 DATE AS OF CHANGE: 20240410 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-RAD LABORATORIES, INC. CENTRAL INDEX KEY: 0000012208 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 941381833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-07928 FILM NUMBER: 24835982 BUSINESS ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 BUSINESS PHONE: 5107247000 MAIL ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 FORMER COMPANY: FORMER CONFORMED NAME: BIO RAD LABORATORIES INC DATE OF NAME CHANGE: 19920703 8-K 1 bio-20240410.htm 8-K bio-20240410
0000012208false00000122082024-04-102024-04-100000012208us-gaap:CommonClassAMember2024-04-102024-04-100000012208us-gaap:CommonClassBMember2024-04-102024-04-10


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report:   April 10, 2024
(Date of earliest event reported)

BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)

Commission File Number: 1-7928
 
Delaware 94-1381833
(State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.)
 
1000 Alfred Nobel Dr.
Hercules, California 94547
(Address of principal executive offices, including zip code)
 
(510)724-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange
Class B Common Stock, Par Value $0.0001 per share 
BIO.B
 New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐




ITEM 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 10, 2024, Dr. Andrew Last, the Executive Vice President, Chief Operating Officer (and principal operating officer) of Bio-Rad Laboratories, Inc. (the “Company”), notified the Company that he intends to retire from his position by early September 2024. In order to ensure a smooth transition, Dr. Last will remain in his current position while the Company conducts a search for his successor.

A copy of the press release announcing the retirement of Dr. Last is furnished with this report as Exhibit 99.1.



ITEM 9.01    Financial Statements and Exhibits
Exhibit
Number 		 Description
99.1 
104.1Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document





SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  
  BIO-RAD LABORATORIES, INC.
   
Date:April 10, 2024By:/s/ Norman Schwartz
   Norman Schwartz
   President and Chief Executive Officer


 EX-99.1 2 bio-8k4102024xex991.htm EX-99.1 Document



Exhibit 99.1

Press Release

Bio-Rad's Chief Operating Officer Andrew Last to Retire

HERCULES, Calif.— April 10, 2024 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of Bio-Rad’s executive leadership team to ensure a smooth transition while the company conducts a search for his successor.

Dr. Last joined Bio-Rad in April of 2019 with over 30 years of experience in global operations management spanning the life sciences.

“Andy’s extensive operations experience, technical acumen, and leadership abilities have been invaluable to Bio-Rad over the past five years,” said Norman Schwartz, Bio-Rad President and CEO. “We have made significant progress on our transformational objectives, including cost structure, core processes, and supply chain improvements, while effectively navigating various macroeconomic challenges.”

Dr. Last stated, “When I reflect on my tenure at Bio-Rad, I am most proud of the team we have built and the operations and management systems we have put in place. I am confident that these accomplishments have positioned Bio-Rad well for the next phase of its continued journey of transformation and growth.”

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.


Investor Contact:
Edward Chung, Investor Relations
510-741-6104
ir@bio-rad.com

Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
cc@bio-rad.com
1
 EX-101.SCH 3 bio-20240410.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bio-20240410_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 bio-20240410_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Common Class B [Member] Common Class B [Member] Entity Information [Line Items] Entity Information [Line Items] Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer Class of Stock [Domain] Class of Stock [Domain] Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Written Communications Written Communications Title of 12(b) Security Title of 12(b) Security Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Document and Entity Information [Abstract] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Common Class A [Member] Common Class A [Member] Document Type Document Type Amendment Flag Amendment Flag Class of Stock [Axis] Class of Stock [Axis] Entity File Number Entity File Number Entities [Table] Entities [Table] Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 6 bio-20240410_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information Document
Apr. 10, 2024
Entity Information [Line Items]  
Entity Central Index Key 0000012208
Entity Emerging Growth Company false
Written Communications false
Entity Incorporation, State or Country Code DE
Document Type 8-K
Document Period End Date Apr. 10, 2024
Entity Registrant Name BIO-RAD LABORATORIES, INC.
Entity File Number 1-7928
Entity Tax Identification Number 94-1381833
Entity Address, Address Line One 1000 Alfred Nobel Dr.
Entity Address, City or Town Hercules
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94547
City Area Code (510)
Local Phone Number 724-7000
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Amendment Flag false
Common Class A [Member]  
Entity Information [Line Items]  
Title of 12(b) Security Class A Common Stock, Par Value $0.0001 per share
Trading Symbol BIO
Security Exchange Name NYSE
Common Class B [Member]  
Entity Information [Line Items]  
Title of 12(b) Security Class B Common Stock, Par Value $0.0001 per share
Trading Symbol BIO.B
Security Exchange Name NYSE
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 3 22 1 false 2 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Document Sheet http://www.bio-rad.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports bio-20240410.htm bio-20240410.xsd bio-20240410_def.xml bio-20240410_lab.xml bio-20240410_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bio-20240410.htm": { "nsprefix": "bio", "nsuri": "http://www.bio-rad.com/20240410", "dts": { "inline": { "local": [ "bio-20240410.htm" ] }, "schema": { "local": [ "bio-20240410.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "bio-20240410_def.xml" ] }, "labelLink": { "local": [ "bio-20240410_lab.xml" ] }, "presentationLink": { "local": [ "bio-20240410_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://www.bio-rad.com/role/DocumentandEntityInformationDocument", "longName": "0000001 - Document - Document and Entity Information Document", "shortName": "Document and Entity Information Document", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:EntityEmergingGrowthCompany", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240410.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:EntityEmergingGrowthCompany", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240410.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class A [Member]", "label": "Common Class A [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class B [Member]", "label": "Common Class B [Member]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "bio_DocumentandEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bio-rad.com/20240410", "localname": "DocumentandEntityInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Document and Entity Information [Abstract]", "label": "Document and Entity Information [Abstract]", "documentation": "Document and Entity Information [Abstract]" } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0000012208-24-000025-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000012208-24-000025-xbrl.zip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bio-20240410_htm.xml IDEA: XBRL DOCUMENT 0000012208 2024-04-10 2024-04-10 0000012208 us-gaap:CommonClassAMember 2024-04-10 2024-04-10 0000012208 us-gaap:CommonClassBMember 2024-04-10 2024-04-10 0000012208 false 8-K 2024-04-10 BIO-RAD LABORATORIES, INC. 1-7928 DE 94-1381833 1000 Alfred Nobel Dr. Hercules CA 94547 (510) 724-7000 false false false false Class A Common Stock, Par Value $0.0001 per share BIO NYSE Class B Common Stock, Par Value $0.0001 per share BIO.B NYSE false